Ebenbuild
Key Facts
| Invested since | 2022 |
| Based in | Bavaria |
About the company
Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software tools that generate precise patient-specific simulation models of lungs based on patient data, so-called digital twins of the lungs. These enable pinpoint individual medical decisions for intensive care patients with acute respiratory distress syndrome (ARDS). In this way, Ebenbuild aims to make a significant contribution to improving treatment as well as reducing mortality.
Do you want to
know more about this company?
Ebenbuild in the news
Zum Artikel
Improving ARDS treatment with digital twins: Ebenbuild secures seed financing round led by Bayern Kapital and High-Tech Gründerfonds
More startups from Life Sciences
Exit
GILUPI developed a nanostructured detector, which is temporarily inserted into the bloodstream. The aim is to spot specific blood cells in vivo and thus to detect diseases in a very …
To the complete profileof GILUPI
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and …
To the complete profileof Nebula Biocides
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer …
To the complete profileof Abalos
Exit
KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the …
To the complete profileof KSK Diagnostics
mo:re has developed a groundbreaking lab platform, combining automation and software for planning, executing, and analysis of cell culture studies. The user-friendly platform aims to simplify cell culture, making organoids …
To the complete profileof mo:re
CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in …
To the complete profileof CustomSurg
Exit
multiBIND develops innovative solutions for molecular biology, healthcare and agriculture. bioDECONT® and bioCLEAN represent biocompatible disinfection and decontamination in laboratories, hospitals and agriculture.
To the complete profileof multiBIND
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
To the complete profileof PreComb
Semi-Exit
Photonics Healthcare enables doctors to monitor cellular oxygen.
To the complete profileof Photonics Healthcare
The company was founded in 2022 and is headquartered at the STIMULATE research campus in Magdeburg’s “science-harbour”. The scientific company is a spin-off by scientists from the Otto-von-Guericke-University Magdeburg. The …
To the complete profileof RAYDIAX
PEPperPRINT produces customized ultra-high density peptide microarrays and uses individualized peptide libraries for drug development, antibody characterization, and protein biomarker discovery.
To the complete profileof PEPperPRINT
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …
To the complete profileof Refoxy Pharma